Key Takeaways
- A quarter with no Revlimid: Revenue fell to ₹651 cr from ₹796 cr YoY and net profit halved to ₹132 cr, entirely because the full Revlimid allocation was sold by September and no quantity remained for Q3.
- The "elephant in the room" is March '27: Management reiterated that earnings will drop more than 50–60% when Revlimid contribution declines, and acknowledged the acquisition meant to build a stable base business has not been executed.
- One-third Revlimid allocation starts Q4: Natco will launch in March with a 33% volume share of the total market, but only one month of sale lands in Q4 and FY26 earnings depend on price erosion that management refuses to forecast.
- GLP-1 is the next big bet: India launch of injectable semaglutide is expected March 2026, subject to regulatory approval; the U.S. opportunity remains confidential and unsettled.
- What to watch next quarter: The pace of Revlimid sales under the new allocation, any price erosion clarity from Teva, and whether an acquisition materializes to deploy the cash pile.
The Revlimid Cycle: Where We Are
- Q3 was a zero-Revlimid quarter: All allocation from the prior period was sold off by September end, leaving no quantity for the December quarter; export formulation revenue fell sequentially entirely for this reason.
- New allocation begins in March: Natco will get nearly one-third of total Revlimid market volume as per its settlement, launching in Q4 with only one month of sale; management believes they should have a good year but declined to compare Q4 to the prior year's Q4.
- FY26 earnings hinge on price erosion: Management expects to maintain FY25-level earnings in FY26, but this depends entirely on how much Revlimid pricing erodes; Teva handles marketing and management refused to estimate erosion or give specific guidance.
- The March '27 cliff is confirmed: Management called it "the elephant in the room" and reiterated a drop of more than 50–60% in earnings when Revlimid contribution declines; more clarity expected a year from now.
- Volatility is the model: The company chases big jackpots and is dependent on one or two events; management told investors they must accept this volatility and that backup plans for revenue do not exist.
Rajeev Nannapaneni: "I think that's the elephant in the room, I think you have to accept that earnings will drop in March'27. How much will it drop? I think that's the question I am directly indicating."
GLP-1 Opportunity: Semaglutide
- India launch targeted for March 2026: Subject to regulatory approval and settlement of other issues; DCGI has asked all applicants to do bioequivalent studies and Natco has completed its study and shared data, now awaiting clinical permission.
- Injectable only, API outsourced: Natco is focusing on the injectable form for India and not looking at oral semaglutide at this time; the API is being sourced externally.
- U.S. opportunity remains opaque: The diabetes product (Ozempic) has been settled with Novo Nordisk, but the weight-loss indication has not; management called the U.S. launch date confidential and said first-to-file exclusivity will be determined later.
- Canada partnership with Viatris: Management confirmed Viatris as the partner for Canada but declined to discuss export strategy further.
- Clinical trial timeline: Natco hopes to get clinical permission shortly, complete the trial by end of year, and submit for permission by end of year, all contingent on regulatory clearance.
Pipeline: What Matters Beyond Revlimid
- Everolimus launched in Q3: Benefit expected in Q4; Natco is looking good on this product and some portion will come in Q4.
- Risdiplam is first-to-file: Working with Sun Pharma on a shared profit basis; litigation is in Delhi High Court and the judge has reserved the matter; management hopes to be first generic subject to a positive verdict.
- 24 FTF products in the U.S. pipeline: Biggest products include Revlimid, Wegovy/Ozempic, Olaparib, Ibrutinib (sole FTF), and Erdafitinib (sole FTF); mid-level value products include Carfilzomib 10 mg and Trabectedin; all will play out over the next 7 to 10 years.
- Olaparib timeline is premature: Management declined to give any timeline, saying it depends on the market and some markets have litigation; on the U.S. specifically, management called it a "Para-political question" and refused to answer.
- Bosentan ANDA approved: Launch date not yet announced, bound by confidentiality.
Base Business & Non-Revlimid Growth
- ROW business is the post-'26 anchor: Brazil, Canada, and the Middle East are doing reasonably well; management expects many oncology approvals in Brazil and Canada, with 7–8 approvals expected in the coming year and some good launches in Canada.
- Ex-Revlimid operating margins around 18–20%: Management agreed this is possible depending on the quarter, but declined to provide EBITDA margin on a pre-R&D basis.
- Crop science still losing money: Currently doing about ₹60 cr a year; target is to reach ₹120–150 cr next year to come closer to break-even; the objective is to break even next year.
- India launches ahead: Semaglutide expected March '26, Risdiplam subject to court verdict, and other products in the pipeline; management expects these to contribute to base business growth but declined to give a specific growth number.
Capital Allocation: Cash, Acquisitions & Debt
- Cash is waiting for a deal: Management is actively looking at two acquisitions: one to strengthen the ROW business, another to strengthen the U.S. front end; both would be in therapeutic prescription pharmaceuticals.
- Acquisition strategy acknowledged as a gap: Management admitted they have not been able to execute an acquisition to build a more stable base-level business, calling it "probably one thing you probably didn't get right."
- Dividend kept modest deliberately: The company does not want to use cash on books because it is preserving cash for an acquisition; management believes they will be able to do some transactions.
- Short-term debt is arbitrage, not distress: The ₹200 cr borrowing costs 6% while deposits earn 8%, so breaking deposits to avoid debt makes no sense; debt is payable in 60–90 days and gets paid off by cash flow.
- U.S. tariff contingency: If the U.S. imposes tariffs on pharmaceutical imports from India, the only escape is to buy front-end manufacturing in the U.S.; Natco is looking at a U.S. front end and getting manufacturing would make it interesting.
- Acquisition financing is flexible: Management said it is possible to take debt for acquisitions and will decide the mix of cash and debt when a takeover happens.
Rajeev Nannapaneni: "But what I can strive to do is that we try to build a business which is more stable at a base level by doing an acquisition, which we have not been able to execute, obviously. I will be very honest about it. That's probably one thing you probably didn't get right."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| FY25 PAT | ₹1,800–2,000 cr; management still hopeful to meet this | FY25 end |
| Revlimid allocation | One-third of total market volume begins selling | Q4 FY25 (March launch) |
| FY26 earnings | Maintain same earnings as FY25, subject to Revlimid price erosion | FY26 |
| March '27 earnings drop | More than 50–60% decline when Revlimid contribution falls | March '27 |
| Semaglutide India launch | Injectable GLP-1 launch, subject to regulatory approval | March 2026 |
| Crop science break-even | Reach ₹120–150 cr revenue to come closer to break-even | Next year (FY26) |
| Acquisitions | Two targets: one for ROW business, one for U.S. front end | No timeline given |
Key Metrics
| Metric | Q3 FY25 |
|---|---|
| Consolidated total revenue | ₹651.1 cr, vs ₹795.6 cr in Q3 FY24 |
| Consolidated net profit | ₹132.4 cr, vs ₹212.7 cr in Q3 FY24 |
| Other income | ₹76 cr, includes a one-time pre-tax gain of ₹90 cr from sale of land |
| Cash and liquid investments | ₹3,264 cr as of December 31, 2024 |
| Debt | ₹241 cr as of December 31, 2024 |
| Net cash | ~₹3,000 cr as of December 31, 2024 |
| R&D expenditure | 7% to 8% of net sales typically, 8% to 10% of revenue |
| FY25 PAT expectation | ₹1,800 to ₹2,000 cr, management hopeful of meeting this guidance |
| Revlimid allocation | One-third of total market volume, starting March 2025 |
| Crop Health Sciences revenue | ₹15–₹16 cr per quarter, targeting ₹130–₹140 cr next year to approach breakeven |
| Subsidiary sales (Q3) | ₹109 cr, year-to-date subsidiary sales at ₹408 cr |
| Ex-Revlimid quarterly revenue | ₹475 cr in Q3 FY25 |
| FY27 earnings outlook | Drop of more than 50% to 60% expected post-Revlimid |